ONtrack Diagnostics

Urine assay for the screening of prostate cancer

  • 4-7 Team Size
  • 2019 Founding Year
  • Zurich Location
  • Idea, pre-funding Project Status
  • www.ontrackdiagnostics.com Website
  • HealthCare, diagnostics, medtech Markets

The current screening of prostate cancer is based on the blood measurement of PSA to select men at risk of prostate cancer, but suffers from low specificity: up to 75% of men indicated to perform the biopsy of the prostate eventually do not have cancer. We have patented a new technology that is able to decrease the false positives of PSA to half.


Irina Banzola